Vector Group Reports Third Quarter 2013 Financial Results
Third quarter 2013 revenues were
The results for the three months ended
For the nine months ended
The results for the nine months ended
For the three and nine months ended
Non-GAAP Financial Measures
Adjusted EBITDA, Adjusted Net Income, Adjusted Operating Income and
Tobacco Adjusted Operating Income are financial measures not prepared in
accordance with generally accepted accounting principles ("GAAP"). The
Company believes that Adjusted EBITDA, Adjusted Net Income, Adjusted
Operating Income and Tobacco Adjusted Operating Income are important
measures that supplement discussions and analysis of its results of
operations and enhances an understanding of its operating performance.
The Company believes Adjusted EBITDA, Adjusted Net Income, Adjusted
Operating Income and Tobacco Adjusted Operating Income provide investors
and analysts with a useful measure of operating results unaffected by
differences in capital structures, capital investment cycles and ages of
related assets among otherwise comparable companies. Management uses
Adjusted EBITDA, Adjusted Net Income, Adjusted Operating Income and
Tobacco Adjusted Operating Income as measures to review and assess
operating performance of the Company's business and management and
investors should review both the overall performance (GAAP net income)
and the operating performance (Adjusted EBITDA, Adjusted Net Income,
Adjusted Operating Income and Tobacco Adjusted Operating Income) of the
Company's business. While management considers Adjusted EBITDA, Adjusted
Net Income, Adjusted Operating Income and Tobacco Adjusted Operating
Income to be important, they should be considered in addition to, but
not as substitutes for or superior to, other measures of financial
performance prepared in accordance with GAAP, such as operating income,
net income and cash flows from operations. In addition, Adjusted EBITDA,
Adjusted Net Income, Adjusted Operating Income and Tobacco Adjusted
Operating Income are susceptible to varying calculations and the
Company's measurement of Adjusted EBITDA, Adjusted Net Income, Adjusted
Operating Income and Tobacco Adjusted Operating Income may not be
comparable to those of other companies. Attached hereto as Tables 2, 3,
4 and 5 is information relating to the Company's Adjusted EBITDA,
Adjusted Net Income, Adjusted Operating Income and Tobacco Adjusting
Operating Income for the three and nine months ended
Conference Call to Discuss Third Quarter 2013 Results
As previously announced, the Company will host a conference call and
webcast on Thursday, October 31, 2013 at
A replay of the call will be available shortly after the call ends on
October 31, 2013 through
[Financial Tables Follow]
TABLE 1 |
|||||||||||||||||||||
Three Months Ended |
Nine Months Ended |
||||||||||||||||||||
|
|
||||||||||||||||||||
2013 | 2012 |
2013 |
2012 | ||||||||||||||||||
Revenues* |
$ |
271,516 |
$ |
272,783 |
$ |
761,038 |
$ |
806,983 | |||||||||||||
Expenses: | |||||||||||||||||||||
Cost of goods sold* | 194,991 | 203,749 | 548,377 | 615,682 | |||||||||||||||||
Operating, selling, administrative and general expenses | 25,897 | 25,841 | 74,697 | 73,734 | |||||||||||||||||
Litigation settlement and judgment expense | 87,913 | — | 87,913 | — | |||||||||||||||||
Operating (loss) income | (37,285 | ) | 43,193 | 50,051 | 117,567 | ||||||||||||||||
Other income (expenses): | |||||||||||||||||||||
Interest expense | (33,583 | ) | (25,906 | ) | (99,045 | ) | (78,667 | ) | |||||||||||||
Loss on extinguishment of debt | — | — | (21,458 | ) | — | ||||||||||||||||
Change in fair value of derivatives embedded within convertible debt | 2,800 | 6,040 | 8,299 | (21,020 | ) | ||||||||||||||||
Acceleration of interest expense related to debt conversion | — | (7,072 | ) | — | (14,960 | ) | |||||||||||||||
Equity income from non-consolidated real estate businesses | 9,489 | 12,874 | 16,774 | 20,969 | |||||||||||||||||
Equity (loss) income on long-term investments | (53 | ) | 124 | 770 | (1,205 | ) | |||||||||||||||
(Loss) gain on sale of investment securities available for sale | (99 | ) | 1,640 | 5,110 | 1,640 | ||||||||||||||||
Other, net | 2,871 | 341 | 5,151 | 856 | |||||||||||||||||
(Loss) income before provision for income taxes | (55,860 | ) | 31,234 | (34,348 | ) | 25,180 | |||||||||||||||
Income tax (benefit) expense | (18,969 | ) | 13,302 | (9,287 | ) | 11,043 | |||||||||||||||
Net (loss) income | (36,891 | ) | 17,932 | (25,061 | ) | 14,137 | |||||||||||||||
Less: Net (loss) income attributed to non-controlling interest | — | — | — | — | |||||||||||||||||
Net (loss) income attributed to |
$ |
(36,891 | ) |
$ |
17,932 |
$ |
(25,061 | ) |
$ |
14,137 | |||||||||||
Per basic common share: | |||||||||||||||||||||
Net (loss) income applicable to common shares attributed to |
$ |
(0.40 | ) |
$ |
0.20 |
$ |
(0.27 | ) |
$ |
0.16 | |||||||||||
Per diluted common share: | |||||||||||||||||||||
Net (loss) income applicable to common shares attributed to |
$ |
(0.40 | ) |
$ |
0.20 |
$ |
(0.27 | ) |
$ |
0.16 | |||||||||||
Cash distributions and dividends declared per share | $ | 0.38 | $ | 0.36 | $ | 1.14 | $ | 1.09 | |||||||||||||
* Revenues and Cost of goods sold include excise taxes of
|
|||||||||||||||||||||
TABLE 2 |
|||||||||||||||||||||
Three Months Ended |
Nine Months Ended |
||||||||||||||||||||
|
|
||||||||||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||||||||||
Net (loss) income attributed to |
$ |
(36,891 | ) |
$ |
17,932 |
$ |
(25,061 | ) |
$ |
14,137 | |||||||||||
Interest expense | 33,583 | 25,906 | 99,045 | 78,667 | |||||||||||||||||
Income tax (benefit) expense | (18,969 | ) | 13,302 | (9,287 | ) | 11,043 | |||||||||||||||
Depreciation and amortization | 2,772 | 2,638 | 8,005 | 7,948 | |||||||||||||||||
EBITDA |
$ |
(19,505 | ) |
$ |
59,778 |
$ |
72,702 |
$ |
111,795 | ||||||||||||
Change in fair value of derivatives embedded within convertible debt (a) | (2,800 | ) | (6,040 | ) | (8,299 | ) | 21,020 | ||||||||||||||
Equity loss (gain) on long-term investments (b) | 53 | (124 | ) | (770 | ) | 1,205 | |||||||||||||||
Loss (gain) on sale of investment securities available for sale | 99 | (1,640 | ) | (5,110 | ) | (1,640 | ) | ||||||||||||||
Equity income from non-consolidated real estate businesses (c) | (9,489 | ) | (12,874 | ) | (16,774 | ) | (20,969 | ) | |||||||||||||
Loss on extinguishment of debt | — | — | 21,458 | — | |||||||||||||||||
Acceleration of interest expense related to debt conversion | — | 7,072 | — | 14,960 | |||||||||||||||||
Stock-based compensation expense (d) | 678 | 816 | 1,933 | 2,434 | |||||||||||||||||
Litigation settlement and judgment expense (e) | 87,913 | — | 87,913 | — | |||||||||||||||||
Impact of MSA Settlement (f) | (4,016 | ) | — | (10,963 | ) | — | |||||||||||||||
Other, net | (2,871 | ) | (341 | ) | (5,151 | ) | (856 | ) | |||||||||||||
Adjusted EBITDA |
$ |
50,062 |
$ |
46,647 |
$ |
136,939 |
$ |
127,949 | |||||||||||||
a. | Represents income or losses realized as a result of changes in the fair value of the derivatives embedded in the Company's convertible debt. | ||||
b. | Represents income or losses recognized on long-term investments that the Company accounts for under the equity method. | ||||
c. | Represents equity income realized from the Company's investment in certain real estate businesses that are not consolidated in its financial results. | ||||
d. | Represents amortization of stock-based compensation. | ||||
e. |
Represents expenses primarily associated with a comprehensive
settlement resolving substantially all of the individual Engle
progeny tobacco litigation cases pending in |
||||
f. | Represents the Company's tobacco business's settlement of a long-standing dispute related to the Master Settlement Agreement. | ||||
TABLE 3 |
|||||||||||||||||||||
Three Months Ended |
Nine Months Ended |
||||||||||||||||||||
|
|
||||||||||||||||||||
2013 | 2012 |
2013 |
2012 | ||||||||||||||||||
Net (loss) income attributed to |
$ |
(36,891 | ) |
$ |
17,932 |
$ |
(25,061 | ) |
$ |
14,137 | |||||||||||
Acceleration of interest expense related to debt conversion | — | 7,072 | — | 14,960 | |||||||||||||||||
Change in fair value of derivatives embedded within convertible debt | (2,800 | ) | (6,040 | ) | (8,299 | ) | 21,020 | ||||||||||||||
Non-cash amortization of debt discount on convertible debt | 9,620 | 4,779 | 25,432 | 12,220 | |||||||||||||||||
Loss on extinguishment of 11% Senior Secured Notes due 2015 | — | — | 21,458 | — | |||||||||||||||||
Litigation settlement and judgment expense (a) | 87,913 | — | 87,913 | — | |||||||||||||||||
Impact of MSA Settlement (b) | (4,016 | ) | — | (10,963 | ) | — | |||||||||||||||
Interest income from MSA Settlement (c) | (1,971 | ) | — | (1,971 | ) | — | |||||||||||||||
Total adjustments | 88,746 | 5,811 | 113,570 | 48,200 | |||||||||||||||||
Tax expense related to adjustments | (33,845 | ) | (2,839 | ) | (43,146 | ) | (19,025 | ) | |||||||||||||
Adjusted net income attributed to |
$ |
18,010 |
$ |
20,904 |
$ |
45,363 |
$ |
43,312 | |||||||||||||
Per diluted common share: | |||||||||||||||||||||
Adjusted net income applicable to common shares attributed to |
$ |
0.19 |
$ |
0.23 |
$ |
0.48 |
$ |
0.48 | |||||||||||||
a. |
Represents expenses primarily associated with a comprehensive
settlement resolving substantially all of the individual Engle
progeny tobacco litigation cases pending in |
||||
b. | Represents the Company's tobacco segment's settlement of a long-standing dispute related to the Master Settlement Agreement. | ||||
c. | Represents interest income from the Company's tobacco segment's settlement of a long-standing dispute related to the Master Settlement Agreement. | ||||
TABLE 4 |
||||||||||||||||||||
Three Months Ended |
Nine Months Ended |
|||||||||||||||||||
|
|
|||||||||||||||||||
2013 | 2012 | 2013 | 2012 | |||||||||||||||||
Operating (loss) income |
$ |
(37,285 | ) |
$ |
43,193 |
$ |
50,051 |
$ |
117,567 | |||||||||||
Litigation settlement and judgment expense (a) | 87,913 | — | 87,913 | — | ||||||||||||||||
Impact of MSA Settlement (b) | (4,016 | ) | — | (10,963 | ) | — | ||||||||||||||
Total adjustments | 83,897 | — | 76,950 | — | ||||||||||||||||
Adjusted Operating Income |
$ |
46,612 |
$ |
43,193 |
$ |
127,001 |
$ |
117,567 | ||||||||||||
a. |
Represents expenses primarily associated with a comprehensive
settlement resolving substantially all of the individual Engle
progeny tobacco litigation cases pending in |
||||
b. | Represents the Company's tobacco segment's settlement of a long-standing dispute related to the Master Settlement Agreement. | ||||
TABLE 5 |
||||||||||||||||||||
Three Months Ended |
Nine Months Ended |
|||||||||||||||||||
|
|
|||||||||||||||||||
2013 | 2012 | 2013 | 2012 | |||||||||||||||||
Operating (loss) income from tobacco business |
$ |
(32,974 | ) |
$ |
48,139 |
$ |
62,480 |
$ |
130,244 | |||||||||||
Litigation settlement and judgment expense (a) | 87,913 | — | 87,913 | — | ||||||||||||||||
Impact of MSA Settlement (b) | (4,016 | ) | — | (10,963 | ) | — | ||||||||||||||
Total adjustments | 83,897 | — | 76,950 | — | ||||||||||||||||
Tobacco Adjusted Operating Income |
$ |
50,923 |
$ |
48,139 |
$ |
139,430 |
$ |
130,244 | ||||||||||||
a. |
Represents expenses primarily associated with a comprehensive
settlement resolving substantially all of the individual Engle
progeny tobacco litigation cases pending in |
||||
b. | Represents the Company's tobacco segment's settlement of a long-standing dispute related to the Master Settlement Agreement. |
Sard Verbinnen & Co
212-687-8080
Source:
News Provided by Acquire Media